No hearing loss after repeated courses of tobramycin in cystic fibrosis patients
- 18 January 2010
- journal article
- Published by Taylor & Francis Ltd in Acta Oto-Laryngologica
- Vol. 130 (2), 253-258
- https://doi.org/10.3109/00016480903015150
Abstract
Conclusion: Our results indicate that repeated treatment courses with tobramycin 10 mg/kg (twice daily for 3 weeks) may be safely applied in cystic fibrosis (CF) patients with respect to ototoxicity. The risk of hearing loss in this patient group is less than expected, which could be explained by either unfavourable baseline audiometry or the use of unidentified protective medication, or both. However, due to large inter-individual variations, audiometry screening remains important with respect to the detection of individual outliers. Objectives: Tobramycin is frequently prescribed for CF patients. In this study, hearing loss due to cumulative tobramycin exposure in adult CF patients was investigated. Patients and methods: We retrospectively investigated 19 patients with both baseline and follow-up audiometry before and after repeated courses of intravenous tobramycin (10 mg/kg/day in twice daily administrations for 3 weeks). Pure tone audiometry was performed at 0.250–16 kHz. Results: After repeated courses of tobramycin (median 3, range 1–8), the mean increase per frequency was 2.1 dB (median 0.5 dB, SD 12.6) with large (inter-individual) variations (range –23.5 to 34.5 dB). The pure tone averages (PTA) at 1-2-4 kHz and 8-10-12 kHz increased 1.4 dBHL and 2.3 dBHL, respectively, but were neither statistically significant, nor correlated with the cumulative tobramycin exposure.Keywords
This publication has 18 references indexed in Scilit:
- Intratympanic Dexamethasone for Sudden Sensorineural Hearing Loss After Failure of Systemic TherapyThe Laryngoscope, 2007
- Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis PatientsAntimicrobial Agents and Chemotherapy, 2006
- Early intervention and prevention of lung disease in cystic fibrosis: a European consensusJournal of Cystic Fibrosis, 2004
- Protective Effect of Corticosteroid against the Cytotoxicity of Aminoglycoside Otic Drops on Isolated Cochlear Outer Hair CellsThe Laryngoscope, 2004
- Round Window Application of D-Methionine, Sodium Thiosulfate, Brain-Derived Neurotrophic Factor, and Fibroblast Growth Factor-2 in Cisplatin-Induced OtotoxicityOtology & Neurotology, 2004
- Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside TherapyAntimicrobial Agents and Chemotherapy, 2001
- Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensusEuropean Respiratory Journal, 2000
- Aminoglycoside-induced ototoxicityToxicology Letters, 1990
- Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosidesAntimicrobial Agents and Chemotherapy, 1987
- Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosisAntimicrobial Agents and Chemotherapy, 1987